People taking popular new weight-loss drugs such as Wegovy and Zepbound often celebrate the number of pounds they shed and ...

The company will scale its weight loss offerings ahead of generic GLP-1s coming to the Canadian market in 2026.

Semaglutide, the active ingredient in Wegovy and Ozempic, lowers major cardiac event risk, regardless of how much weight a ...

At this month’s Food and Nutrition Conference and Expo in Nashville, one buzzword dominated conversations – GLP-1 medications. From protein-packed bars, portion-controlled snacks to prepared meals, br ...

To break it down, while hair loss itself is not directly a side effect of the drug, losing weight rapidly, can cause telogen ...

Novo Nordisk (($NVO)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled ‘Wegovy® ...

Novo Nordisk (($NVO)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled ‘Wegovy® ...

Eli Lilly's Q3 results hinge on strong demand for Mounjaro and Zepbound as investors weigh growth drivers against the ...

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

A British mother, 53, reportedly died after taking $26 weight-loss injections at a beauty salon, her daughters have said.

Scientists look to genetics to explain why GLP-1 drugs work for some people but not for others People taking popular new ...

Lilly's GIP/GLP-1 agonist Mounjaro (tirzepatide) also outperformed Ozempic, and the formulation of the drug for obesity, ...